© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
July 04, 2022
“Patients who really need to be screened are not getting screened,” says Ram Pathak, MD.
July 01, 2022
"HIFU allows us to treat where we want and not where we don’t," writes Jennifer Linehan, MD.
June 30, 2022
“These analyses illustrate the critical role for inclusion of mathematical models, evolutionary first principles and computer simulations in trial design. Unlike conventional clinical trials, this approach allows both cohort and patient-specific analyses," said Jingsong Zhang, MD, PhD.
June 29, 2022
"What we still need to trial is the use of treatment intensification or triple therapy in men with high-risk localized and/or locally advanced disease," writes Michael S. Cookson, MD, MMHC.
June 28, 2022
“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.
June 27, 2022
"One of the main goals of our interactions with patients is to increase adherence," said Amy Pfeifer, PharmD, BCPS, CSP.
"We believe this novel treatment strategy will improve the lives of many prostate cancer patients,” said lead study investigator Behfar Ehdaie, MD.
June 22, 2022
The phase 3 PROpel trial showed that adding the PARP inhibitor olaparib to frontline abiraterone acetate significantly improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.
June 21, 2022
Eric J. Small, MD, has been announced as one of the winners of the 10th annual Giants of Cancer Care awards. Small is being recognized for his achievements in the clinical practice and research of genitourinary cancers.
June 16, 2022
The Moffitt research team, in collaboration with scientists at Washington University in St. Louis, wanted to identify alternative resistance mechanisms to enzalutamide and abiraterone in prostate cancer patients.